Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Muscae volitantes — “eye floaters” are those little, transparent threads that you see floating across your eyeball. Generally ...

This drug has the potential to be more targeted than others currently being studied, and we hope it will result in fewer ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s Disease failed to ...

TUESDAY, Oct. 8, 2024 (HealthDay News) -- The brain has a waste-disposal system that clears away junk proteins that ...

Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Outcomes may improve with disease-modifying drugs and lifestyle change if Alzheimer's could be identified earlier.

Saturday marked the 16th year for the Walk to End Alzheimer’s here in Victoria, however, the fight for the disease has been ...